A medical device containing 104 mg MPA (medroxyprogesterone acetate) in 0.65 mL suspension for injection and indicated for long-term female contraception via SC injection into the anterior thigh or abdomen every 13 weeks.

In this study the medication will be administrated subcutaneously (under the skin) in one of the following locations: arms, thigh or abdomen. During a subcutaneous injection, a needle is inserted under the skin, rather than into a vein. 

The Pfizer Clinical Research Unit of Brussels will be conducting research studies in the near future with participants of Chinese descent.

The purpose is to find out how much medication is in breastmilk after intake.

This will help us determine the daily dose a child could potentially be exposed to during breastfeeding, if the nursing mother must take this medicinal product.

For the potential treatment of COVID-19, a respiratory infection caused by the coronavirus, SARS-CoV-2.

The Pfizer Clinical Research Unit Brussels is conducting a study of an investigational drug for a potential treatment of adult and pediatric patients with RSV.